Royalty Pharma's stocks trend and market activity have been a rollercoaster as covered by recent events. Q4 earnings showed some lows against other branded pharmaceuticals stocks, however, significant purchases taking place by asset management firms, such as
Horizon Kinetics, Swiss National Bank, and
AGF Management Ltd., show a bullish trend. This interest is despite some ambiguous financials that put sustainability of the momentum into question.
Analysts maintain that
Royalty Pharma remains an investment-worthy cheap biotech stock. Despite its momentary disappointing performance, Jim Cramer recommends holding the stock, projecting a positive growth story ahead. Amid such recommendations,
Royalty Pharma unveiled a $3B buyback plan, boosting the quarterly dividend, which could attract more investors.
Several institutional owners have been trimming their stakes in the firm. Other significant events included the much-awaited appearance at the
TD Cowen's Healthcare Conference, along with the announcement of a massive 77% profitable investment cash out on
MorphoSys. The company has recently secured significant funding with
Geron Corporation and
Pharmakon Advisors which may positively affect the company’s finances.
Royalty Pharma Stocks News Analytics from Wed, 22 May 2024 07:00:00 GMT to Sat, 22 Mar 2025 06:30:28 GMT -
Rating 5
- Innovation 6
- Information 8
- Rumor -5
